Pathway and evidence strategy
Clarify likely classification, regulatory route, intended use, predicate options, market priorities, and the evidence needed to support a defensible plan.
MEDICAL DEVICE REGULATORY CONSULTING
Make the regulatory decisions that keep your device moving.
Qualira helps medical-device teams connect regulatory pathway, clinical evidence, submissions, and quality work before uncertainty turns into costly rework.
Discuss your program →THE DECISION BEFORE THE DELIVERABLE
More than a document. A plan your program can carry through.
Medical-device regulation affects more than a submission date. It shapes what the team needs to build, test, document, validate, and maintain. When pathway assumptions are weak or evidence needs are defined too late, the result is often extra testing, conflicting inputs, delayed decisions, or a quality system that cannot support the product as it grows.
Qualira brings senior regulatory, clinical, quality, and technical expertise into the same conversation. That makes it easier to evaluate the path in front of your device, identify the work that truly matters, and keep cross-functional decisions aligned from development through commercialization.
WHERE QUALIRA HELPS
Support that follows the actual pressure points in a device program.
Submission readiness and delivery
Connect the device story, testing, risk management, labeling, technical documentation, and submission content so reviewers can see the logic behind the evidence.
Clinical and quality alignment
Keep clinical planning, design controls, quality records, and regulatory expectations from moving as separate workstreams with separate assumptions.
Focused support when the stakes change
Add senior perspective for agency interactions, quality remediation, inspection response, product changes, global expansion, or a high-consequence internal review.
HOW THE WORK FITS TOGETHER
Regulatory work is strongest when it reflects the whole program.
A regulatory plan cannot be separated cleanly from product claims, design decisions, testing strategy, clinical evidence, and quality records. A change in intended use can affect the evidence burden. A weak predicate comparison can change what needs to be tested. Incomplete design controls can make the underlying rationale harder to defend. Each decision has a downstream cost when it is made in isolation.
Qualira works with teams to make those dependencies visible early. For a new product, that may mean deciding whether the likely route is a 510(k), De Novo, PMA, IDE, or another regulatory path before technical plans become fixed. For an established product, it may mean reviewing a change, resolving a quality-system gap, or preparing a response that addresses the underlying issue rather than only the immediate observation.
The right level of support depends on the program. Some teams need an experienced partner from early strategy through submission and post-market work. Others need a focused assessment, additional execution capacity, or an independent perspective before a high-stakes decision. Qualira meets teams at the point where clearer judgment can protect their timeline and options.
THE QUESTIONS THAT SHAPE THE WORK
Bring experienced judgment to the decisions that affect everything after them.
Medical-device teams often come to a regulatory decision with only part of the picture in view. A product may be technically ready to move forward while its intended use, evidence plan, labeling, and predicate logic are still being developed on separate tracks. The task is not simply to identify a requirement. It is to decide what path creates a clear, proportionate case for the device without asking the organization to solve the wrong problem.
Classification and pathway fit
Classification is an early business decision as much as a regulatory one. It informs the likely route to market, the rigor of the evidence package, the timing of agency engagement, and the development work that needs to be ready. Qualira helps teams assess pathway fit before a presumed route becomes a fixed and costly assumption.
Evidence that supports the claim
Not every device needs the same combination of bench performance, software validation, biocompatibility, human factors, clinical evidence, or literature support. The right plan depends on the device, its claims, its technology, and the remaining questions that a reviewer will need answered. A focused evidence strategy helps teams invest effort where it strengthens the case.
Submission content that tells one story
Strong submissions are coherent. The device description, intended use, predicate comparison, risk documentation, testing, labeling, and summaries need to support the same rationale. When the underlying work comes from different functions, Qualira helps the team expose conflicts early and turn complex source material into a clear submission position.
Quality readiness that can support growth
Quality systems are not separate from regulatory progress. Design history, risk management, supplier controls, corrective actions, and change management all influence the records behind a submission and the organization’s ability to respond after market entry. Qualira helps connect quality planning to the product and regulatory decisions already in motion.
REAL PROGRAM EXPERIENCE
Experienced support matters most when the original plan is no longer enough.
Qualira has helped a novel-device team reframe its FDA engagement, moving from a more burdensome anticipated route toward a De Novo path supported by animal data. In another program, the team completed on-site design history file remediation and quality-system work before the client obtained 510(k) clearance and began commercialization.
Those programs required more than a single regulatory deliverable. They required the regulatory, technical, clinical, and quality work to support the same decision. That is the difference between checking a task off a list and building a program that can withstand review.
View client outcomes →A USEFUL FIRST CONVERSATION
Bring the question your team cannot afford to get wrong.
Are we pursuing the right pathway for this device and intended use?
What evidence, testing, and documentation need to be in place before we commit to the plan?
Where are regulatory, clinical, and quality assumptions falling out of alignment?
Do we need a full partner, targeted expertise, or an independent readiness review?
FREQUENTLY ASKED QUESTIONS
Frequently asked questions
When should a medical device company bring in a regulatory consultant?
Bring in senior regulatory support before a decision will narrow your options, such as finalizing intended use, selecting a pathway, locking a testing plan, preparing a pre-submission, or scaling a quality system. Late-stage support can still be useful for a gap assessment, focused submission effort, or remediation, but earlier involvement gives a team more room to choose the right path.
Can Qualira support both strategy and execution?
Yes. Qualira can help teams assess the pathway and evidence plan, then carry the work into submissions, clinical programs, quality systems, agency interactions, and post-market responsibilities. The level of support is shaped around the decision and the capacity already inside the company.
Does every medical device need the same regulatory path?
No. The appropriate path depends on the device, intended use, risk, technology, available predicates, evidence needs, target markets, and quality-system readiness. A useful consulting engagement makes those trade-offs clear before downstream work becomes difficult to change.
What if our team already has regulatory staff?
Qualira can complement an internal team when a program needs added capacity, an independent review, specialized technical expertise, or senior support for a critical decision. The goal is to strengthen the work already underway, not create unnecessary layers.
TALK WITH QUALIRA